The US Food and Drug Administration approved oveporexton, marketed as Orzeyful, on August 5, 2026 — the first orexin receptor agonist ever approved for adults with narcolepsy type 1. Developed by Takeda Pharmaceuticals over 15 years since the candidate compound was first identified in 2011, the drug is the first designed to treat the root cause of the sleep disorder rather than merely managing its symptoms.
Narcolepsy type 1 affects roughly 3 million people worldwide and is caused by the loss of approximately 70,000 neurons in the brain's hypothalamus that produce orexin, a neuropeptide essential for regulating the sleep-wake cycle. Without orexin, patients experience extreme daytime sleepiness, nighttime wakefulness, sleep paralysis, hallucinations, and in type 1, cataplexy — sudden muscle weakness triggered by emotions.
Orzeyful works by mimicking orexin and activating its receptors, helping to stabilize wakefulness and sleep circuits. In two phase III clinical trials enrolling 273 participants, those receiving the drug showed significant improvements in staying awake during the day and sleeping at night, along with reductions in cataplexy, sleep paralysis, and hallucinations.
The approval has been celebrated by patients and clinicians alike. Tyler Chapman, a 19-year-old University of Tennessee student who volunteered for the clinical trials, described it as life-changing after previously trying more than a dozen medications with severe side effects. Stanford sleep specialist Emmanuel Mignot, who led the trials and was instrumental in discovering orexin's link to narcolepsy, said patients become more or less like normal people on the drug.
The narcolepsy therapeutics market is projected to exceed $6.4 billion annually by the early 2030s, attracting major pharmaceutical companies including Alkermes, which is developing its own orexin agonist. Insomnia was the most common side effect, occurring in about 60% of users versus 1% on placebo, though the drug is pending DEA scheduling before it reaches pharmacies.
